Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Biosyent ( (TSE:RX) ).
BioSyent reported strong financial results for the fourth quarter and full year 2025, with total sales rising 10% in Q4 and 23% for the year to $43.1 million, driven by double-digit growth in its Canadian pharmaceutical portfolio and triple-digit gains in international pharma and legacy businesses. Profitability remained robust, with EBITDA up 30% for the year, net income after tax increasing 24% to $9.0 million, and return on average equity improving to 24%, supporting higher dividends, continued share buybacks and reinvestment in key brands including FeraMAX, Tibella/Tibelia and Inofolic.
The company also advanced its strategic diversification by generating $2.4 million in 2025 sales from the Tibelia assets acquired in 2024 and completing the acquisition of Oral Science Inc., expanding its footprint in specialized dental hygiene and oral health products. Management highlighted BioSyent’s 62 consecutive profitable quarters and capital-light, cash-generating model as the foundation for ongoing growth investments and shareholder returns, positioning the business for further expansion in both pharmaceutical and oral health markets in 2026.
The most recent analyst rating on (TSE:RX) stock is a Buy with a C$16.50 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.
Spark’s Take on RX Stock
According to Spark, TipRanks’ AI Analyst, RX is a Outperform.
Biosyent’s overall stock score is driven by strong financial performance and positive technical indicators. The company’s robust revenue growth and profitability, combined with a positive market trend, support a favorable outlook. However, valuation metrics suggest the stock is fairly priced, and potential overbought conditions warrant caution.
To see Spark’s full report on RX stock, click here.
More about Biosyent
BioSyent Inc. is a Canadian specialty healthcare company listed on the TSX Venture Exchange under the symbol RX. The company acquires, in-licenses, markets and distributes innovative pharmaceutical and oral health products through its Canadian pharma, international pharma and oral health business units, focusing on therapies with established safety profiles and demonstrated benefits for patients and healthcare professionals.
Average Trading Volume: 5,114
Technical Sentiment Signal: Buy
Current Market Cap: C$175.7M
For detailed information about RX stock, go to TipRanks’ Stock Analysis page.